or a pharmaceutically acceptable salt thereof, wherein:

Y is O;

ring A is  or  and X is N or CH, wherein

R_{18} and R_{19} are each independently selected from H, halo, (C_1-C_6) alkyl, (C_1-C_6) haloalkyl, (C_1-C_6) haloalkoxy, (C_6-C_{10}) aryl, (C_3-C_{10}) cycloalkyl, 4-14 membered heterocycloalkyl, phenyl, 5-14 membered heteroaryl, -CN, -NO_2, -OR^a, -SR^a, -$C(O)R^a$, -$C(O)NR^aR^a$, -$C(O)OR^a$, -NHR^a, -NR^aR^a, and -$NR^aC(O)R^a$, wherein the (C_1-C_6) alkyl, (C_1-C_6) haloalkyl, (C_1-C_6) haloalkoxy, (C_6-C_{10}) aryl, (C_3-C_{10}) cycloalkyl, 4-14 membered heterocycloalkyl, phenyl, and 5-14 membered heteroaryl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, (C_1-C_6) alkyl, -CN, and -OH; or

R_{18} and R_{19} taken together with the atoms to which they are attached form a fused C_{3-7} cycloalkyl ring or a fused 4- to 10-membered heterocycloalkyl ring;

R_{10} and R_{11} are H;

each R_{13} is independently selected from the group consisting of -H; halo; -OH; -CN; optionally substituted (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_1-C_6) haloalkoxy; -NH_2; --NH(C_1-C_6)alkyl; -N(C_1-C_6 alkyl)$_2$; and (C_3-C_6) cycloalkyl;

each R_{14} is independently selected from the group consisting of H, halo, and (C_1-C_6) alkyl

R_{15} is H;

each R_{12} is independently selected from the group consisting of -H and halo;

each R^a is independently selected from the group consisting of -H, (C_1-C_6) alkyl, (C_3-C_{10}) cycloalkyl, 4-14 membered heterocycloalkyl, and (4-14 membered heterocycloalkyl)-(C_1-C_4) alkylene-, wherein the (C_1-C_6) alkyl, (C_3-C_{10}) cycloalkyl, 4-14 membered heterocycloalkyl, and (4-14 membered heterocycloalkyl)-(C_1-C_4) alkylene- of R^a are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from (C_1-C_6) alkyl, (C_1-C_6) alkoxy, and -C(O)O(C_1-C_4) alkyl;

the subscript n is an integer of 1, 2, 3, or 4;

the subscript m is an integer of 1, 2, 3, 4, or 5; and

the subscript p is an integer of 0, 1, 2, 3, or 4.

[0008] In one example, the compound of Formula I' is a compound of Formula I:



I

wherein:

X is selected from N and C-H;

Y is O, S, SO, SO_2, NH, or N-(C_1-C_6 alkyl);

R_{13} is selected from –H, halo, -CN, and optionally substituted C_{1-6} alkyl;

R_{12} is -H or halo;

 is optionally substituted with one, two, three, or four groups independently selected from the group consisting of halo, and C_1-C_6 alkyl, wherein "∿∿∿" indicate points of attachment;



is selected from the group consisting of 

, 

, and 

;

wherein R_{18} and R_{19} are selected from the group consisting of H, halo, -CN, optionally substituted C_1-C_6 alkyl, $C(O)NR_5R_6$, optionally substituted 5 or 6-membered heteroaryl, and optionally substituted C_1-C_6 alkoxy; or

when 

is 

, R_{18} and R_{19} can be joined together to form a 5 or 6-membered optionally substituted cycloalkyl or heterocycloalkyl;

R_5 and R_6 are selected from the group consisting of H, optionally substituted C_{1-6} alkyl, or R_5 and R_6 taken together with the nitrogen to which they are attached to form a 5- or 6-membered optionally substituted heterocycle; and

m and n are each independently 1 or 2;

provided that when 

is 

and X is C-H, R_{19} is not optionally substituted C_1-C_6 alkyl, halo, or optionally substituted C_1-C_6 alkoxy.

[0009] In one example, the compound of Formula I' is a compound of Formula II:



II

or a pharmaceutically acceptable salt thereof, wherein:

R_{16} is selected from the group consisting of –CN and $–CO\text{-}NR_5R_6$;

R_{17} is selected from H and optionally substituted C_1-C_6 alkoxy;

R_{13} is selected from the group consisting of –H, halo, -CN, or optionally substituted C_{1-6} alkyl;

R_{12} is -H or halo

 is optionally substituted with one, two, three, or four groups independently selected from the group consisting of halo, and C_1-C_6 alkyl, wherein "~~~" indicate points of attachment;

R_5 and R_6 are each independently selected from the group consisting of H, optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_6 heterocycloalkyl, and optionally substituted C_1-C_6 cycloalkyl;

Y is O, S, SO, SO_2, NH, or N-(C_1-C_6 alkyl); and

m and n are each independently 1 or 2.

[00010] In one aspect, the disclosure includes a pharmaceutical composition comprising a compound described herein, and a pharmaceutically acceptable carrier or excipient.

[00011] In another example, the disclosure includes a method of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase, comprising administering to a subject in need thereof a therapeutically effective amount of a compound described herein, or a pharmaceutical composition thereof.

[00011a] In one aspect, the disclosure includes the compound of any of claims 1-37 for use in therapy.

[00011b] In another aspect, the disclosure includes the pharmaceutical composition comprising a compound as described herein, and a pharmaceutically acceptable carrier or excipient for use in therapy

[00011c] In another aspect, the disclosure includes a use of a compound as described herein or a pharmaceutical composition as described herein in the manufacture of a medicament for treating cancer.

Detailed Description of the Invention

[00012] Abbreviations and Definitions

[00013] The following abbreviations and terms have the indicated meanings throughout:

Claims

1. A compound of Formula I':



(I')

or a pharmaceutically acceptable salt thereof, wherein:

Y is O;

ring A is  or  and X is N or CH, wherein

R_{18} and R_{19} are each independently selected from H, halo, (C_1-C_6) alkyl, (C_1-C_6) haloalkyl, (C_1-C_6) haloalkoxy, (C_6-C_{10}) aryl, (C_3-C_{10}) cycloalkyl, 4-14 membered heterocycloalkyl, phenyl, 5-14 membered heteroaryl, -CN, -NO_2, -OR^a, -SR^a, -$C(O)R^a$, -$C(O)NR^aR^a$, -$C(O)OR^a$, -NHR^a, -NR^aR^a, and -$NR^aC(O)R^a$, wherein the (C_1-C_6) alkyl, (C_1-C_6) haloalkyl, (C_1-C_6) haloalkoxy, (C_6-C_{10}) aryl, (C_3-C_{10}) cycloalkyl, 4-14 membered heterocycloalkyl, phenyl, and 5-14 membered heteroaryl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, (C_1-C_6) alkyl, -CN, and -OH; or

R_{18} and R_{19} taken together with the atoms to which they are attached form a fused C_{3-7} cycloalkyl ring or a fused 4- to 10-membered heterocycloalkyl ring;

R_{10} and R_{11} are H;

each R_{13} is independently selected from the group consisting of -H; halo; -OH; -CN; optionally substituted (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_1-C_6) haloalkoxy; -NH_2; --NH(C_1-C_6)alkyl; -N(C_1-C_6 alkyl)$_2$; and (C_3-C_6) cycloalkyl;

each R_{14} is independently selected from the group consisting of H, halo, and (C_1-C_6) alkyl

R_{15} is H;

each R_{12} is independently selected from the group consisting of -H and halo;

each R^a is independently selected from the group consisting of -H, (C_1-C_6) alkyl, (C_3-C_{10}) cycloalkyl, 4-14 membered heterocycloalkyl, and (4-14 membered heterocycloalkyl)-(C_1-C_4) alkylene-, wherein the (C_1-C_6) alkyl, (C_3-C_{10}) cycloalkyl, 4-14 membered heterocycloalkyl, and (4-14 membered heterocycloalkyl)-(C_1-C_4) alkylene- of R^a are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from (C_1-C_6) alkyl, (C_1-C_6) alkoxy, and -C(O)O(C_1-C_4) alkyl;

the subscript n is an integer of 1, 2, 3, or 4;

the subscript m is an integer of 1, 2, 3, 4, or 5; and

the subscript p is an integer of 0, 1, 2, 3, or 4.

2. The compound of claim 1, having Formula I'b, I'c or I'd:



,

(I'b)



(I'd).

3. The compound of claim 1 or 2, having Formula (I'b-1):



(I'b-1).

4. The compound of claim 1 or 2, having Formula (I'b-2):



(I'b-2).

5. The compound of claim 1 or 2, having Formula (I'd-1):



(I'd-1).

6. The compound of claim 1 or 2, having Formula (I'd-2):



(I'd-2).

7. The compound of any of claims 1-6, wherein R_{18} and R_{19} are each independently selected from -H, halo, (C_1-C_6) alkyl, phenyl, (C_3-C_{10}) cycloalkyl, 4-14 membered heterocycloalkyl, 5-14 membered heteroaryl, -CN, -O(C_1-C_6) alkyl, -C(O)(C_1-C_6) alkyl, -$C(O)NH_2$, -C(O)NH(C_1-C_6) alkyl, -C(O)N((C_1-C_6) alkyl)$_2$, -C(O)O(C_1-C_6) alkyl, -NH(C_1-C_6) alkyl, -N((C_1-C_6) alkyl)$_2$, -NHC(O)(C_1-C_6) alkyl, -O(C_1-C_4 alkylene-(4-14 membered heterocycloalkyl)), O(C_1-C_6 alkoxy-C_1-C_6 alkyl)), and $–NH_2$

8. The compound of any of claims 1-6, wherein R_{18} and R_{19} are each independently H, halo, CN, R^aNHC(O)-, $–OR^a$ or 5- or 6-membered heteroaryl optionally substituted with (C_1-C_6) alkyl.

9. The compound of any of claims 1-8, wherein the subscript m is 1.

10. The compound of any of claims 1-8, wherein the subscript n is 1.

11. The compound of any of claims 1-8, wherein the subscript p is 1.

12. The compound of claim 1, having Formula I:



I

wherein:

X is selected from N and C-H;

Y is O;

R_{13} is selected from –H, halo, -CN, and optionally substituted $C_{1\text{-}6}$ alkyl;

R_{12} is -H or halo;

 is optionally substituted with one, two, three, or four groups independently selected from the group consisting of halo, and C_1-C_6 alkyl, wherein "〰" indicate points of attachment;

 is selected from the group consisting of , , and ;

wherein R_{18} and R_{19} are selected from the group consisting of H, halo, -CN, optionally substituted C_1-C_6 alkyl, $C(O)NR_5R_6$, optionally substituted 5 or 6-membered heteroaryl, and optionally substituted C_1-C_6 alkoxy; or

when  is , R_{18} and R_{19} can be joined together to form a 5 or 6-membered optionally substituted cycloalkyl or heterocycloalkyl;

R_5 and R_6 are selected from the group consisting of H, optionally substituted $C_{1\text{-}6}$ alkyl; and

m and n are each independently 1 or 2.

13. The compound of claim 12, wherein R_{19} is selected from the group consisting of optionally substituted C_1-C_6 alkoxy and –CN.

14. The compound of claims 1-2, wherein  is , , , , , , ,



15. The compound of any of claims 13-14, wherein X is N.

16. The compound of any of claims 13-15, wherein R_{13} is H.

17. The compound of any of claims 13-16, wherein  is not substituted.

18. The compound of any of claims 13-17, wherein R_{12} is halo.

19. The compound of any of claims 13-18, wherein R_{12} is para fluoro.

20. The compound of claim 1 or 12, wherein the compound is selected from:

Comp.	Structure	IUPAC Name
7		1-N'-(4-fluorophenyl)-1-N-(4-pyrido[3,2-d]pyrimidin-4-yloxyphenyl)cyclopropane-1,1-dicarboxamide

12		1-N-[4-(7-chloropyrido[3,2-d]pyrimidin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
13		1-N-[4-(7-bromopyrido[3,2-d]pyrimidin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
16		1-N'-(4-fluorophenyl)-1-N-[4-(7-methoxypyrido[3,2-d]pyrimidin-4-yl)oxyphenyl]cyclopropane-1,1-dicarboxamide
19		1-N'-[2,5-difluoro-4-(7-methoxypyrido[3,2-d]pyrimidin-4-yl)oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
28		1-N-[4-(6,7-dimethoxypyrido[3,2-d]pyrimidin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
29		1-N'-[3-chloro-4-(6,7-dimethoxypyrido[3,2-d]pyrimidin-4-yl)oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

30		1-N'-[4-(6,7-dimethoxypyrido[3,2-d]pyrimidin-4-yl)oxy-3-fluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
31		1-N'-[4-(6,7-dimethoxypyrido[3,2-d]pyrimidin-4-yl)oxy-2-fluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
32		1-N'-[2-chloro-4-(6,7-dimethoxypyrido[3,2-d]pyrimidin-4-yl)oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
33		1-N'-[4-(6,7-dimethoxypyrido[3,2-d]pyrimidin-4-yl)oxy-2-methylphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
34		1-N'-[4-(6,7-dimethoxypyrido[3,2-d]pyrimidin-4-yl)oxy-2,3-difluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
35		1-N'-[4-(6,7-dimethoxypyrido[3,2-d]pyrimidin-4-yl)oxy-2,5-difluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

43		1-N-[4-(6,7-dimethylpyrido[3,2-d]pyrimidin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
52		1-N'-(4-fluorophenyl)-1-N-[4-(6,7,8,9-tetrahydropyrimido[5,4-b]quinolin-4-yloxy)phenyl]cyclopropane-1,1-dicarboxamide
57		1-N-[4-(6-cyano-7-methoxypyrido[3,2-d]pyrimidin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
65		1-N'-(4-fluorophenyl)-1-N-[4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide
66		1-N'-[3-chloro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

67		1-N'-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
68		1-N-(4-fluorophenyl)-1-N'-[4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxy-3-methylphenyl]cyclopropane-1,1-dicarboxamide
69		1-N'-[2-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
70		1-N'-[2-chloro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
71		1-N-(4-fluorophenyl)-1-N'-[4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxy-2-methylphenyl]cyclopropane-1,1-dicarboxamide
72		1-N'-[2,5-difluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

73		1-N'-[2,3-difluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
74		1-N-(4-fluorophenyl)-1-N'-[3-methoxy-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide
75		1-N'-[3-cyano-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
76		1-N'-[3,5-difluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
78		1-N'-(4-fluorophenyl)-1-N-[4-[6-methoxy-7-(2-methoxyethoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide
79		1-N'-[3-fluoro-4-[6-methoxy-7-(2-methoxyethoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
80		1-N'-[3-chloro-4-[6-methoxy-7-(2-methoxyethoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

81		1-N'-[2-fluoro-4-[6-methoxy-7-(2-methoxyethoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
82		1-N'-[2,3-difluoro-4-[6-methoxy-7-(2-methoxyethoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
83		1-N'-[2,5-difluoro-4-[6-methoxy-7-(2-methoxyethoxy)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
85		1-N'-(4-fluorophenyl)-1-N-(4-pyrido[3,4-d]pyrimidin-4-yloxyphenyl)cyclopropane-1,1-dicarboxamide
88		1-N-[4-(6-chloropyrido[3,4-d]pyrimidin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
91		1-N'-(4-fluorophenyl)-1-N-[4-(6-methoxypyrido[3,4-d]pyrimidin-4-yl)oxyphenyl]cyclopropane-1,1-dicarboxamide

129		1-N'-(4-fluorophenyl)-1-N-[4-[7-(1-methylpyrazol-4-yl)pyrido[3,2-d]pyrimidin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide
139		1-N-[4-[(6,7-dimethoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
140		1-N'-[4-[(6,7-dimethoxy-1,5-naphthyridin-4-yl)oxy]-3-fluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
141		1-N'-[3-chloro-4-[(6,7-dimethoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
142		1-N'-[4-[(6,7-dimethoxy-1,5-naphthyridin-4-yl)oxy]-2,5-difluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
149		1-N'-(4-fluorophenyl)-1-N-[4-[[6-methoxy-7-(2-methoxyethoxy)-1,5-naphthyridin-4-yl]oxy]phenyl]cyclopropane-1,1-dicarboxamide

150		1-N'-[3-fluoro-4-[[6-methoxy-7-(2-methoxyethoxy)-1,5-naphthyridin-4-yl]oxy]phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
151		1-N'-[3-chloro-4-[[6-methoxy-7-(2-methoxyethoxy)-1,5-naphthyridin-4-yl]oxy]phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
152		1-N'-[2,5-difluoro-4-[[6-methoxy-7-(2-methoxyethoxy)-1,5-naphthyridin-4-yl]oxy]phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
153		1-N'-[2,5-difluoro-4-[[6-methoxy-7-(2-morpholin-4-ylethoxy)-1,5-naphthyridin-4-yl]oxy]phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
157		1-N-[4-(2,3-dihydro-[1,4]dioxino[2,3-b][1,5]naphthyridin-6-yloxy)phenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
158		1-N'-[4-(2,3-dihydro-[1,4]dioxino[2,3-b][1,5]naphthyridin-6-yloxy)-3-fluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
159		1-N'-[3-chloro-4-(2,3-dihydro-[1,4]dioxino[2,3-b][1,5]naphthyridin-6-yloxy)phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

164		1-N-[4-[(6-cyano-7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
165		1-N'-[4-[(6-cyano-7-methoxy-1,5-naphthyridin-4-yl)oxy]-3-fluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
166		1-N'-[3-chloro-4-[(6-cyano-7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
167		1-N-[4-[(6-carbamoyl-7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
168		1-N'-[4-[(6-carbamoyl-7-methoxy-1,5-naphthyridin-4-yl)oxy]-3-fluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
169		1-N'-[4-[(6-carbamoyl-7-methoxy-1,5-naphthyridin-4-yl)oxy]-3-chlorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

172		1-N'-(4-fluorophenyl)-1-N-[4-[[7-methoxy-6-(methylcarbamoyl)-1,5-naphthyridin-4-yl]oxy]phenyl]cyclopropane-1,1-dicarboxamide
173		1-N'-[3-fluoro-4-[[7-methoxy-6-(methylcarbamoyl)-1,5-naphthyridin-4-yl]oxy]phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
174		1-N-[4-[[6-(dimethylcarbamoyl)-7-methoxy-1,5-naphthyridin-4-yl]oxy]phenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
176		1-N'-[2,5-difluoro-4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
181		1-N-[4-[(6-amino-7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
182		1-N'-(4-fluorophenyl)-1-N-[4-[[7-methoxy-6-(1-methylpyrazol-4-yl)-1,5-naphthyridin-4-yl]oxy]phenyl]cyclopropane-1,1-dicarboxamide

183		1-N'-(4-fluorophenyl)-1-N-[4-[[7-methoxy-6-(1H-pyrazol-4-yl)-1,5-naphthyridin-4-yl]oxy]phenyl]cyclopropane-1,1-dicarboxamide
184		1-N'-(4-fluorophenyl)-1-N-[4-[[7-methoxy-6-(2-methylpyrazol-3-yl)-1,5-naphthyridin-4-yl]oxy]phenyl]cyclopropane-1,1-dicarboxamide
189		1-N'-(4-fluorophenyl)-1-N-[4-[[6-(1-methylpyrazol-4-yl)-1,5-naphthyridin-4-yl]oxy]phenyl]cyclopropane-1,1-dicarboxamide

or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a compound of any of claims 1-20, and a pharmaceutically acceptable carrier or excipient.

22. The compound of any of claims 1-20 for use in therapy.

23. The pharmaceutical composition comprising a compound of any of claims 1-20, and a pharmaceutically acceptable carrier or excipient for use in therapy.

24. Use of a compound of any of claims 1-20 or a pharmaceutical composition of claim 21 in the manufacture of a medicament for treating cancer.